Advertisement
YAZ(R) (drosperinone and ethinyl estradiol tablets) is indicated for theprevention of pregnancy.
Forward-Looking Statement
Any statements contained in this press release that refer to future eventsor other non-historical facts are forward-looking statements that reflectWatson's current perspective of existing trends and information as of the dateof this release. Except as expressly required by law, Watson disclaims anyintent or obligation to update these forward-looking statements. Actualresults may differ materially from Watson's current expectations dependingupon a number of factors affecting Watson's business. These factors include,among others, patents and other intellectual property rights held bycompetitors and other third parties and the uncertainty of the outcome oflitigation related to such patents and intellectual property rights; theimpact of competitive products and pricing; market acceptance of and continueddemand for Watson's products; difficulties or delays in manufacturing; andother risks and uncertainties detailed in Watson's periodic public filingswith the Securities and Exchange Commission, including but not limited toWatson's Annual Report on Form 10-K for the year ended December 31, 2006.
YAZ(R) is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
SOURCE Watson Pharmaceuticals, Inc.
